<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486211</url>
  </required_header>
  <id_info>
    <org_study_id>15GRNT25680021</org_study_id>
    <nct_id>NCT02486211</nct_id>
  </id_info>
  <brief_title>Amantadine to Speed Awakening After Cardiac Arrest</brief_title>
  <acronym>AWAKE</acronym>
  <official_title>Amantadine to Speed Awakening After Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jon Rittenberger, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates if amantadine will increase the rate of awakening in patients
      resuscitated from cardiac arrest but comatose (not following commands) after their
      resuscitation. Half of the participants will receive amantadine and the other will receive
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amantadine has been used to help patients awaken following traumatic brain injury, but it has
      not been studied in patients with anoxic brain injury.

      Amantadine is a dopamine agonist and may help with stimulating the brain to awaken. The
      investigators will randomize subjects who remain comatose 72 hours following resuscitation
      from cardiac arrest to either amantadine or placebo. They will be treated with either
      amantadine or placebo for 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Awakening (Number of Patients Who Are Able to Follow Commands)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Defined as the ability to follow commands (i.e. &quot;wiggle your toes&quot; &quot;open your eyes&quot; &quot;squeeze my fingers&quot;. This corresponds to a Full Outline of Unresponsiveness motor score of 4. FOUR (full outline of unresponsiveness) measures the following: Eye Response, Motor Response, Brainstem Reflexes, and Respirations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Awakening</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Defined as the time from enrollment to awakening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)</measure>
    <time_frame>during study drug administration (7 days)</time_frame>
    <description>detected by EEG monitoring with or without clinical correlate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea or Vomiting</measure>
    <time_frame>during study drug administration (7 days)</time_frame>
    <description>nausea requiring antiemetic medications or clinical vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe or Intracranial Bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>Bleeding that does not stop with direct pressure, requires transfusion, or occurs in the intracranial vault</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Coma</condition>
  <condition>Heart Arrest</condition>
  <condition>Anoxia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>100mg twice per day for 7 days at 0600 and 1200</description>
    <arm_group_label>Amantadine</arm_group_label>
    <other_name>Symmetrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non traumatic cardiac arrest

          -  Age 18 and older

          -  Defibrillation and/or chest compressions by healthcare providers

          -  Return of spontaneous circulation

        Exclusion Criteria:

          -  Written do not attempt resuscitation (DNAR) reported to providers before randomization

          -  Known prisoner or pregnancy

          -  Lack of motor response to pain and absent N20 response on somatosensory evoked
             potentials prior to randomization

          -  Initial CT demonstrating brain edema (defined as grey white ratio &lt;1.2)

          -  Presence of malignant pattern on EEG at time of randomization

          -  Next of kin unwilling to provide supportive care for at least one week after
             enrollment

          -  Presently using other dopaminergic agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon C Rittenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Main Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deacconness</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Mercy Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <results_first_submitted>June 28, 2019</results_first_submitted>
  <results_first_submitted_qc>November 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2019</results_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jon Rittenberger, MD</investigator_full_name>
    <investigator_title>Associate Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>heart arrest</keyword>
  <keyword>resuscitation</keyword>
  <keyword>seizures</keyword>
  <keyword>hypothermia, induced</keyword>
  <keyword>Amantadine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02486211/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amantadine</title>
          <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg twice per day for 7 days at 0600 and 1200</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
        </group>
        <group group_id="B2">
          <title>Amantadine</title>
          <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg BID for 7 days at 0600 and 1200</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="9"/>
                    <measurement group_id="B2" value="54" spread="16"/>
                    <measurement group_id="B3" value="55" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Awakening (Number of Patients Who Are Able to Follow Commands)</title>
        <description>Defined as the ability to follow commands (i.e. &quot;wiggle your toes&quot; &quot;open your eyes&quot; &quot;squeeze my fingers&quot;. This corresponds to a Full Outline of Unresponsiveness motor score of 4. FOUR (full outline of unresponsiveness) measures the following: Eye Response, Motor Response, Brainstem Reflexes, and Respirations.</description>
        <time_frame>up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amantadine</title>
            <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg twice per day for 7 days at 0600 and 1200</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Awakening (Number of Patients Who Are Able to Follow Commands)</title>
          <description>Defined as the ability to follow commands (i.e. &quot;wiggle your toes&quot; &quot;open your eyes&quot; &quot;squeeze my fingers&quot;. This corresponds to a Full Outline of Unresponsiveness motor score of 4. FOUR (full outline of unresponsiveness) measures the following: Eye Response, Motor Response, Brainstem Reflexes, and Respirations.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Awakening</title>
        <description>Defined as the time from enrollment to awakening</description>
        <time_frame>up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amantadine</title>
            <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg BID for 7 days at 0600 and 1200</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Awakening</title>
          <description>Defined as the time from enrollment to awakening</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)</title>
        <description>detected by EEG monitoring with or without clinical correlate</description>
        <time_frame>during study drug administration (7 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amantadine</title>
            <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg BID for 7 days at 0600 and 1200</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)</title>
          <description>detected by EEG monitoring with or without clinical correlate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea or Vomiting</title>
        <description>nausea requiring antiemetic medications or clinical vomiting</description>
        <time_frame>during study drug administration (7 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amantadine</title>
            <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg BID for 7 days at 0600 and 1200</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea or Vomiting</title>
          <description>nausea requiring antiemetic medications or clinical vomiting</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe or Intracranial Bleeding</title>
        <description>Bleeding that does not stop with direct pressure, requires transfusion, or occurs in the intracranial vault</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amantadine</title>
            <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg BID for 7 days at 0600 and 1200</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe or Intracranial Bleeding</title>
          <description>Bleeding that does not stop with direct pressure, requires transfusion, or occurs in the intracranial vault</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Amantadine</title>
          <description>100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Amantadine: 100mg BID for 7 days at 0600 and 1200</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
Placebo: Placebo comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tongue swelling</sub_title>
                <description>Tongue swelling secondary to tongue bite.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <description>seizure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jon Rittenberger</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>4126479489</phone>
      <email>rittjc@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

